Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
Inventors
Assignees
Publication Number
US-10792338-B2
Publication Date
2020-10-06
Expiration Date
2028-08-13
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of Erythropoietin and about 100-300 mg per cm2 wound tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject. Unit dosage forms, pharmaceutical compositions, cosmetic compositions and formulations comprising Erythropoietin and/or Fibronectin are also disclosed.
Core Innovation
The invention relates to compositions containing Erythropoietin (EPO) and Fibronectin (FN) and their use in therapeutic and cosmetic applications, particularly for promoting wound healing, connective tissue reconstruction, and treating ischemia. The invention details methods for topical administration of EPO and FN at specific dosages to accelerate wound healing and promote angiogenesis, extracellular matrix production, and reepithelialization. The invention also covers unit dosage forms, pharmaceutical and cosmetic compositions containing these components.
The problem addressed by the invention concerns impaired wound healing, especially in conditions such as diabetes, aging, and other skin maladies. Existing wound healing is often delayed or completely impaired due to factors like reduced proliferation of cells, decreased new blood vessel formation, and diminished extracellular matrix synthesis, leading to chronic wounds with major health and socioeconomic impacts. The invention aims to overcome these problems by using specific topical dosages of EPO and FN to enhance wound healing and connective tissue reconstruction, and to treat ischemia related tissue damage.
Claims Coverage
The patent includes one independent claim focusing on a pharmaceutical composition containing defined amounts of Erythropoietin and Fibronectin along with specific excipients. This claim defines the composition's components and concentrations.
Pharmaceutical composition comprising specific dosages of erythropoietin and fibronectin
A pharmaceutical composition comprising about 10-30 μg/mL Erythropoietin, about 100-200 μg/mL Fibronectin, about 0.20% Methyl Paraben, about 9% laureth and isoparaffin and polyacrylamide, about 12% deionized water and a phosphate buffer solution.
The independent claim defines a topical pharmaceutical composition combining specific concentrations of Erythropoietin and Fibronectin with particular excipients, thereby covering the inventive formulation for promoting wound healing, connective tissue reconstruction, and treating ischemia as described in the invention.
Stated Advantages
Topical application of the specified doses of Erythropoietin and Fibronectin significantly accelerates wound healing.
Combination of Erythropoietin and Fibronectin promotes angiogenesis and increases microvessel density in wounded tissues.
The synergistic effect of Erythropoietin and Fibronectin enhances extracellular matrix production, particularly collagen synthesis, thereby promoting connective tissue reconstruction.
Treatment with these compositions increases levels of vascular endothelial growth factor (VEGF) at wound sites, supporting neovascularization.
Erythropoietin reduces apoptosis sensitivity by upregulating anti-apoptotic proteins in wound tissue.
Documented Applications
Promoting wound healing for various wound types including incisional, excisional, post-surgical, pressure ulcers, burn wounds, chronic wounds, and wounds inflicted by diabetes.
Promoting connective tissue reconstruction in skin conditions and maladies, such as sagging, fine lines, wrinkles, age spots, photo damage, blemishes, dry skin, acne, sores, warts, and appearance of aged skin.
Topical treatment of ischemia by promoting angiogenesis and tissue repair in ischemic tissues.
Use in cosmetic compositions for skin care, such as anti-aging and skin rejuvenation applications.
Interested in licensing this patent?